Slide footer goes here if required 1 -- 1 of 21 -- -- 2 of 21 -- 3 -- 3 of 21 -- 4 -- 4 of 21 -- 5 -- 5 of 21 -- 6 -- 6 of 21 -- -- 7 of 21 -- ■ ■ Operational Growth • • • • • • • • • • • • • • • -- 8 of 21 -- • • • • • • • • • • • • • • ■ ■ Operational Growth -- 9 of 21 -- -- 10 of 21 -- -- 11 of 21 -- -- 12 of 21 -- -- 13 of 21 -- • – – – – – – – • – – – – – – – – • – • – – – – -- 14 of 21 -- -- 15 of 21 -- -- 16 of 21 -- • • • • • • • • 17 -- 17 of 21 -- -- 18 of 21 -- -- 19 of 21 -- -- 20 of 21 -- = Achieved POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA Sum of Program Change Sum of Region Change Sum of Check Change Sum of Program Change Sum of Region Change Sum of Check Change Phase III Phase I/II P US AKEEGA (niraparib/abiraterone) P US AKEEGA (niraparib/abiraterone) P CARVYKTI (ciltacabtagene autoleucel) P TAR-200 (RIS/gemcitabine plus cetrelimab) P EU L1 Prostate cancer metastatic castration- resistant (MAGNITUDE) L1 Prostate cancer metastatic castration- resistant (MAGNITUDE) Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4) Non muscle invasive bladder cancer (SR-1 Early Data) P US TALVEY (talquetamab) TALVEY (talquetamab) P BALVERSA (erdafitinib) TAR-210 (RIS/erdafitinib) P EU Relapsed Refractory Multiple Myeloma P EU Relapsed Refractory Multiple Myeloma Urothelial cancer (THOR) Non muscle invasive bladder cancer (Early Data) P US ERLEADA (apalutamide) P US BALVERSA (erdafitinib) RYBREVANT (amivantamab) TAR-200 (RIS/gemcitabine plus cetrelimab) P EU Tablet Reduction P EU Urothelial cancer (THOR) Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON) Non muscle invasive bladder cancer (SunRISe-1 Update) TECVAYLI (teclistamab) P US CARVYKTI (ciltacabtagene autoleucel) IMBRUVICA (ibrutinib) P BALVERSA (erdafitinib) P EU Relapsed Refractory Multiple Myeloma Biweekly Dosing P EU Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4) Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO) Tumor Agnostic (RAGNAR) P US EDURANT (rilpivirine) amivantamab / lazertinib RYBREVANT (amivantamab) P EU HIV pediatric 2-12 year old Non Small Cell Lung Cancer 2L (MARIPOSA-2) Solid Tumors (GIC2001) OPSUMIT (macitentan) amivantamab / lazertinib P JNJ-2113 P EU Pediatric pulmonary arterial hypertension Non Small Cell Lung Cancer (MARIPOSA) Psoriasis P US macitentan w/tadalafil FDC P macitentan w/tadalafil FDC nipocalimab P EU Pulmonary arterial hypertension Pulmonary arterial hypertension (A DUE) Rheumatoid Arthritis P US RYBREVANT (amivantamab) P SPRAVATO (esketamine) P nipocalimab P EU Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON) Treatment Resistant Major Depressive Disorder (ESCAPE-TRD) Hemolytic disease of the fetus and newborn US amivantamab / lazertinib TREMFYA (guselkumab) EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) Crohn's Disease US amivantamab / lazertinib P TREMFYA (guselkumab) Non Small Cell Lung Cancer (MARIPOSA) Ulcerative Colitis Monotherapy Johnson & Johnson Innovative Medicine Pipeline – Key Events in 2023* *This information is as of October 17, 2023 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. -- 21 of 21 --